FDA approves Replimune melanoma drug previously rejected twice

How fast it spread

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Sources (11)

• 
  Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling. Barron's · 46d ago
• 
  Pharmalittle: We're reading about Replimune's melanoma drug, a Medicare policy change, and more STAT · 46d ago broke it first
• 
  Replimune rebounds to win FDA approval of melanoma drug BioPharma Dive · 46d ago
• 
  FDA approves Replimune's Tudriqev melanoma drug on third try qz.com · 46d ago
• 
  Replimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections Endpoints News · 46d ago
• 
  REPL Stock Slumps 11% After-Hours Yahoo Finance · 46d ago
• 
  Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen Yahoo Finance · 46d ago
• 
  US FDA approves Replimune's skin cancer drug after prior rejections Reuters · 46d ago
• 
  Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle Fierce Pharma · 46d ago
• 
  FDA Approves Replimune’s Melanoma Drug on Third Attempt WSJ · 46d ago
• 
  FDA approves Replimune melanoma drug previously rejected twice STAT · 46d ago broke it first

Related trends